Kimberly Snyder, APRN
Adult Health · Richmond, INNPI 1265416341
Payments from drug & device makers
Across 144 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$435
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$209
- Teva Pharmaceuticals USA, Inc.$157
- Otsuka America Pharmaceutical, Inc.$132
- Novo Nordisk$120
- Neurocrine Biosciences, Inc.$115
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,46898%
- Other$502%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $435 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $209 |
| Teva Pharmaceuticals USA, Inc. | 7 | $157 |
| Otsuka America Pharmaceutical, Inc. | 7 | $132 |
| Novo Nordisk | 7 | $120 |
| Neurocrine Biosciences, Inc. | 6 | $115 |
| Astellas Pharma US Inc | 5 | $109 |
| Amgen | 7 | $108 |
| Lundbeck LLC | 5 | $106 |
| AstraZeneca | 7 | $103 |
| GSK | 5 | $86 |
| Abbott | 3 | $86 |
| Pfizer | 5 | $83 |
| Exact Sciences | 5 | $79 |
| Lilly USA, LLC | 5 | $75 |
| Novartis | 4 | $74 |
| Eisai Inc. | 4 | $70 |
| Insulet Corporation | 2 | $41 |
| Radius Health, Inc. | 2 | $41 |
| Bayer | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Edwards Lifesciences | 1 | $32 |
| Acadia Pharmaceuticals Inc | 2 | $29 |
| Phathom Pharmaceuticals, Inc. | 2 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
How this compares
$2,518 in reported general payments places this provider in the 80th percentile of 391 adult health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 140 | $181,360 |
| EliquisApixaban | 130 | $103,984 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 124 | $89,824 |
| MounjaroTirzepatide | 66 | $82,505 |
| LinzessLinaclotide | 62 | $40,192 |
| JanuviaSitagliptin Phosphate | 28 | $29,184 |
| QuliptaAtogepant | 11 | $27,328 |
| XareltoRivaroxaban | 20 | $21,969 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 36 | $17,829 |
| JardianceEmpagliflozin | 30 | $17,713 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $14,835 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $14,342 |
| Aripiprazole | 103 | $14,270 |
| MyrbetriqMirabegron | 22 | $14,065 |
| CreonLipase/Protease/Amylase | 15 | $13,974 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $120 | $181,360140 claims |
| PfizerEliquis, Premarin | $83 | $108,207142 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $86 | $102,270156 claims |
| Lilly USA, LLCMounjaro | $75 | $82,50566 claims |
| AbbVieLinzess, Qulipta, Creon | $435 | $81,49488 claims |
| Johnson & JohnsonXarelto | $13 | $21,96920 claims |
| Astellas Pharma US IncMyrbetriq | $109 | $14,06522 claims |
| AstraZenecaSymbicort | $103 | $4,56219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 391 adult health providers in Indiana.
Other adult health in Richmond
- Natalie KingRichmond$10K
- Joyce PittmanIndianapolis$177K
- Jennifer BerryIndianapolis$50K
- Tajuana DavisZionsville$31K
- Patricia Damron-RobinsonMerrillville$20K
- Terry RidgeCarmel$20K
- Kristine StarcevichMerrillville$19K
- Jolyn Holliday VezaGreenfield$17K
- Anna MatulewiczMishawaka$14K
- Ludmila Pichugena-EmersonMiddlebury$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.